Jobs / United States / Abbvie INC
Principal Research Scientist I
Abbvie INC · 🇺🇸 North Chicago, IL, US
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 94 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Abbvie INC paid sponsored hires in similar roles4 certified filings for “PRINCIPAL RESEARCH SCIENTIST I” (Molecular and Cellular Biologists) in IL: $105k–$155k, median $120k. Most were filed at wage level III (50%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Abbvie INC
The US Department of Labor certified 177 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 94 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Abbvie INC →
About the role
Overview: The Translational Safety Pharmacology department provides rigorous in vitro and in vivo safety assessments and fit-for-purpose assay development to enable informed discovery and development decisions. Cardiovascular safety pharmacology is central to advancing safe, high-quality medicines. The Principal Research Scientist will serve as the in vivo cardiovascular safety pharmacology subject-matter leader, providing scientific and strategic leadership across rodent, canine, and nonhuman-primate models. This role leads the design, execution, interpretation, and reporting of cardiovascular safety studies; advances GLP and regulatory readiness; and partners across a matrixed organization to deliver reproducible, decision-ready data. Responsibilities: • Lead the design, execution, quality, interpretation, and reporting of in vivo cardiovascular safety pharmacology studies across rodent, canine, and nonhuman-primate models. • Provide scientific leadership for cardiovascular assessments, including hemodynamics, ECG and electrophysiology, pressure-volume loops, echocardiography, vascular reactivity, thrombosis, and relevant disease models. • Develop, optimize, validate, and implement fit-for-purpose cardiovascular assays and models; author and implement SOPs that support quality, consistency, and regulatory readiness. • Champion data quality, reproducibility, and scientifically sound interpretation; mentor scientists; communicate study strategy, results, and risk assessments to senior leadership, cross-functional stakeholders, and regulatory-facing teams; and advance cardiovascular safety pharmacology capabilities, workflows, and technologies. • Manage (directly and indirectly) team members in a matrixed environment to help plan, coordinate, and prioritize studies. • PhD in physiology, pharmacology, toxicology, or a related field, with 10+ years of relevant experience in cardiovascular biology, safety pharmacology, or a closely related discipline. • Demonstrated cardiovascular biology and safety pharmacology expertise, including the ability to design, execute, interpret, and report in vivo cardiovascular studies. • Experience with rodent and large-animal studies, including canine and nonhuman-primate models. • Experience authoring and implementing SOPs, with working knowledge of GLP, quality systems, and regulatory-ready documentation. • Strong written and verbal scientific communication skills; demonstrated ability to lead in a matrixed environment, apply critical thinking, troubleshoot complex study issues, and manage multiple priorities effectively. • At least one year of previous people management experience Applicable only to applicants applying to a position in any location with pay disclosure requirements under state or local law: • The compensation range described below is the range of possible base pay compensation that the Company believes in good faith it will pay for this role at the time of this posting based on the job grade for this position. Individual compensation paid within this range will depend on many factors including geographic location, and we may ultimately pay more or less than the posted range. This range may be modified in the future. • We offer a comprehensive package of benefits including paid time off (vacation, holidays, sick), medical/dental/vision insurance and 401(k) to eligible employees. • This job is eligible to participate in our long-term incentive programs. Note: No amount of pay is considered to be wages or compensation until such amount is earned, vested, and determinable. The amount and availability of any bonus, commission, incentive, benefits, or any other form of compensation and benefits that are allocable to a particular employee remains in the Company's sole